Higher event risk with DAPT with potent P2Y12-antagonist than with clopidogrel-based treatment
ESC 2017 - Barcelona3' education - Aug. 29, 2017
Prof.dr. Clemens von Birgelen - Medisch Spectrum Twente, Enschede, The Netherlands
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.